Immunovaccine hires John Trizzino as ceo

Vaccine specialist brings 25 years of experience to the role

Immunovaccine, a Canadian developer of vaccines, has appointed John Trizzino as chief executive. He will also join the board of directors of the firm upon joining on 1 October.

Trizzino has focused his career on vaccine development, manufacturing and distribution in the US and worldwide.

He joins Immunovaccine from Novavax, a clinical-stage vaccine company in Rockville, Maryland, where he was senior vice president.

Prior to this, he held senior executive positions at MedImmune, acquired by AstraZeneca, and ID BioMedical, now part of GlaxoSmithKline.

He began his broad-based career in vaccines at Henry Schein.

‘As our development programme accelerates with a second cancer vaccine in the clinic, we are pleased to be joined by someone with John's experience in partnering, licensing and distribution,’ said Albert Scardino, chairman of Immunovaccine.

‘The next phase of our development includes expanding the commercial potential of our early stage research partnerships. That is John's specialism. He knows the public markets, private financing and government contracting, and with his broad experience in the biotechnology industry, we anticipate a high level of visibility for our pioneering delivery platform and our vaccines.’

Immunovaccine develops vaccines for treating cancer and for the prevention of infectious disease.

The firm's DepoVax platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Zika outbreak gives rise to global fears

Zika may not be a new virus but its newly confirmed ability to cause foetal brain abnormalities makes the search for a treatment or a vaccine a high priority. Dr Sarah Houlton looks at the latest initiatives
Research & Development

Immunovaccine licenses cancer vaccine from Merck KGaA

Builds on clinical studies by formulating vaccine in DepoVax system
Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Pharmaceutical

Moderna named a top employer by Science for eleventh consecutive year

Moderna was recognised for its commitment to continuous innovation and a culture that reflects the values of its employees.
Pharmaceutical

Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit

As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare
Pharmaceutical

Takeda and Innovent Biologics partner to advance next-gen oncology medicines

Takeda will establish manufacturing of two next-generation late-stage investigational medicines in the US and will receive exclusive commercialisation rights for IBI363 and IBI343 outside the US and China
Subscribe now